South America Pharmaceutical Glass Vials and Ampoules Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Pharmaceutical Glass Vials and Ampoules Market Trends and Insights

Expansion of Injectable Drug Manufacturing

Injectable medicine projects are increasing demand for qualified vials and ampoules in the South America Pharmaceutical Glass Vials and Ampoules Market. Novo Nordisk committed DKK 8 billion (USD 1.10 billion) in April 2025 to expand injectable treatment production in Montes Claros, Brazil, with completion expected in 2028.^{[1]Novo Nordisk, “Novo Nordisk Announces DKK 8 Billion Investment in Expansion of Production Facilities in Montes Claros, Brazil,” Novo Nordisk, novonordisk.com} The project includes aseptic lines, cold storage, and a quality-control laboratory, while each fill-finish line needs a validated container system before medicines can be released. Hipolabor announced BRL 330 million (USD 58.9 million) in phased investment for 2026 to 2028, and Aché began operating a 40 million-unit injectable and ophthalmic facility in Pernambuco in February 2026. These projects create demand near manufacturing clusters and make fast supplier substitution difficult. Suppliers that meet delivery and validation requirements are better placed to serve this demand.

Growth of Vaccine and Biosimilar Production

Vaccine and biosimilar production supports the South America Pharmaceutical Glass Vials and Ampoules Market because these medicines are commonly administered by injection. Brazil and India formalized 3 Productive Development Partnerships in February 2026 to support local production of biosimilars for nivolumab and pertuzumab, while Blau Farmacêutica completed domestic development of a pembrolizumab biosimilar in January 2026. These products need containers that protect sensitive formulations, with Type I borosilicate glass relevant for protein stability and extractables control. Fiocruz's Novo Centro de Processamento Final is designed to produce 120 million vials annually once operational.^{[2]SKAN, “Partnership for Global Health: The Collaboration with Bio-Manguinhos,” SKAN, skan.com} Patent expiries for pembrolizumab in 2028 and semaglutide in 2026 are encouraging biosimilar preparation. This activity shifts procurement toward recurring supply agreements established early in the production plan.

Rising Demand for Type I Glass Containers

Type I borosilicate glass is increasingly used for injectable therapies requiring high chemical resistance in the South America Pharmaceutical Glass Vials and Ampoules Market. SCHOTT Pharma outlined a 2025 FIOLAX® Pro roadmap for Type I clear borosilicate tubing, and its Itupeva facility has supplied regional ampoules, vials, and cartridges for more than 25 years. Gerresheimer, Stevanato Group, and SCHOTT Pharma created the Alliance for RTU in October 2024 to support the development of ready-to-use sterile vials and cartridges. RTU formats use Type I tubing and can eliminate the need for washing, sterilization, and depyrogenation at fill-finish sites. A change from Type II to Type I requires a new container-closure qualification cycle. This can extend supply agreements and strengthen demand for formats with established technical documentation.

Increasing Regional Pharmaceutical Self-Sufficiency

Pharmaceutical self-sufficiency programs are supporting local validation of packaging systems in the South America Pharmaceutical Glass Vials and Ampoules Market. Brazil's pharmaceutical sector generated BRL 220 billion (USD 39.3 billion) in 2026, and IQVIA projected 10.6% growth in the sector. The federal government has signed 31 Productive Development Partnerships since 2023 for medicines, vaccines, and strategic health inputs, increasing the need for suppliers that support regulatory submissions. A dedicated injectable facility began operating in Joinville, with an investment exceeding BRL 160 million (USD 28.1 million), extending production beyond established corridors. Locally qualified containers can reduce lead times and the risk of breakage. Their availability can influence how quickly new plants reach commercial output.^{[3]EMS, “EMS Recebe Aval da Anvisa e Consolida Potência na Saúde com OZIVY,” EMS, ems.com.br}

High Energy Intensity of Pharmaceutical Glass Melting

Glass furnaces for pharmaceutical products operate above 1,500°C, exposing the South America Pharmaceutical Glass Vials and Ampoules Market to fluctuations in energy costs. Energy accounted for 25% to 35% of tubular-glass conversion costs in the supplied research, while Brazilian natural-gas prices can reflect import parity and exchange-rate movements. These conditions pressure converters when pharmaceutical customers cannot accept higher packaging prices. Parglass plans to invest USD 85 million in a 100% electric glass furnace at Villa Hayes, Paraguay. Smaller converters may struggle to fund comparable programs and face greater cost and sustainability pressure. This can favor established suppliers with diversified furnace networks and energy arrangements.

Stringent Container-Closure and Extractables Qualification

Qualification requirements slow the introduction of new glass formats in the South America Pharmaceutical Glass Vials and Ampoules Market. ANVISA's RDC 982/2025 entered into force in July 2025 and introduced risk-based GMP certification criteria, while reviews of sterile manufacturing per format, limiting the use of barrier systems and validated container-closure integrity. Suppliers need documentation on container-closure integrity, extractables and leachables, and hydrolytic resistance to support registration dossiers. ANMAT published Disposición 5146/2026 in August 2026 for closed-system manufacturing of large-volume parenteral solutions. Qualification can take 12 to 18 months for each format, which limits rapid responses to disruptions. The process raises quality assurance and rewards suppliers with existing regulatory standing.^{[4]Agência Nacional de Vigilância Sanitária, “RDC 982/2025: Critérios de Gestão de Risco para Concessão de Certificados de Boas Práticas de Fabricação,” Agência Nacional de Vigilância Sanitária, dlmconsult.com.br}

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Vials Lead Injectable Packaging Demand

Vials held 70.12% of the South America Pharmaceutical Glass Vials and Ampoules Market share in 2025 and are forecast to grow at an 8.57% CAGR through 2031. Vaccines, hospital injectables, and biologics all rely on vial formats across the region. Vials are compatible with lyophilization, which supports the stability of some biologics and biosimilars. This makes the format important as the therapeutic mix becomes more complex. Public vaccination programs also use single-dose and multi-dose vial configurations.

Ampoules continue to play an important role in single-dose medicines and emergency treatments. Their hermetic seal and tamper-evident form suit analgesics, contrast agents, and critical-care medicines. Demand is especially relevant in Argentine hospital formularies and other South American hospital systems. SGD Pharma returned to FCE Pharma 2026 in São Paulo with its tubular glass ampoule portfolio. The South America Pharmaceutical Glass Vials and Ampoules Market will continue to require both formats because their clinical uses remain distinct.

By Glass Type: Type I Borosilicate Supports Sensitive Injectables

Type I borosilicate glass accounted for 61.45% of revenue in 2025 and is forecast to grow at an 8.78% CAGR through 2031. Its resistance to hydrolytic attack is important for parenteral medicines that are sensitive to pH changes or alkali leachables. Biologics and protein-based therapies have increased the need for these container properties. The South America Pharmaceutical Glass Vials and Ampoules Market size for Type I formats is supported by local biosimilar and specialty-injectable projects. Suppliers with consistent tubing quality can be better positioned in regulated applications.

Type II-treated soda-lime glass remains relevant for aqueous small-molecule injectables, where chemical sensitivity is lower. Type III soda-lime glass continues to be used for dry powders and some non-parenteral applications. SCHOTT Pharma's FIOLAX® Pro roadmap shows how suppliers are emphasizing Type I glass for higher-value uses. Changing from Type II to Type I requires a full qualification cycle at a fill-finish facility. This can encourage early adoption of Type I formats when new biologic capacity is planned.

By Manufacturing Process: Tubular Forming Leads While RTU Conversion Grows

Tubular glass forming accounted for 55.42% of revenue in 2025, while ready-to-use sterile conversion is forecast to expand at an 8.62% CAGR through 2031. Tubular forming provides dimensional control and efficient output for standard vials and ampoules. It remains central to the South America Pharmaceutical Glass Vials and Ampoules Market because regional customers procure these products at large volumes. Molded glass forming is used for major ampoule and infusion-bottle applications. Tubular formats face increasing demand from customers who need precise, validated dimensions.

Ready-to-use conversion removes washing, sterilization, and depyrogenation steps at fill-finish sites. This can offset the higher unit cost of the format for biologic CDMOs and specialty injectable producers. The Alliance for RTU is intended to reduce validation barriers by aligning technical standards and qualification documentation. Gerresheimer began a EUR 30 million (USD 32.4 million) RTU-vial expansion at Wertheim in October 2025, with completion targeted for mid-2027. These additions may expand access to RTU formats through existing commercial networks.

By Application: Biologics and Biosimilars Drive Growth

Vaccines held 30.36% revenue share in 2025, while biologics and biosimilars are forecast to grow at an 8.81% CAGR through 2031. Vaccine production provides an established demand base for vials. The South America Pharmaceutical Glass Vials and Ampoules Market share is increasingly influenced by biologic medicines that require more exacting containment. Patent expiries and public procurement programs are supporting local biosimilar development. This changes the mix of containers sought by pharmaceutical manufacturers.

Blau Farmacêutica's January 2026 pembrolizumab biosimilar program demonstrates growing domestic monoclonal antibody capability. EMS received ANVISA approval in 2025 for OZIVY, its semaglutide biosimilar, produced at a São Paulo peptide plant with capacity for 40 million injectable pens annually. Small-molecule injectables remain important for hospital generics and analgesics. Diagnostic reagents are a stable niche because public health laboratories need sealed containers that preserve reagent shelf life. The South America Pharmaceutical Glass Vials and Ampoules Market also benefits from these recurring diagnostic requirements.

Geography Analysis

Brazil held 34.46% of the South America Pharmaceutical Glass Vials and Ampoules Market share in 2025. The Brazilian pharmaceutical sector generated BRL 220 billion (USD 39.3 billion) in 2026, and domestically owned laboratories accounted for 77.9% of unit volume in the supplied research. SCHOTT Pharma's Itupeva facility employs 500 people and produces ampoules, vials, and cartridges for local customers.

New aseptic capacity in Montes Claros and Pernambuco strengthens Brazil's role in the South America Pharmaceutical Glass Vials and Ampoules Market. These production clusters favor suppliers that can provide shorter delivery routes and lower breakage exposure. Brazil also has an expanding pipeline for generics and biosimilars as patents approach expiry. The country's broad pharmaceutical output supports recurring demand for qualified primary packaging. Container availability can affect the speed at which new plants reach commercial production.

Chile is forecast to grow at a 9.01% CAGR through 2031, the fastest rate among the reported geographies. Specialty pharmaceuticals, cold-chain expansion, and predictable regulatory processes support this outlook. Chile is used as an entry point for international biosimilar launches in South America. Prestige Biopharma's partnership with Dr. Reddy's for Tuznue commercialization is expected to include Chile in later rollout phases. Argentina adds demand through established generic injectables and expanding biologics activity, including Biosidus's bioreactor plant for agalsidase beta supply. Other South American countries contribute import demand for vaccines and generic injectables, often supplied by Brazilian or global converters.